Protocols
36 protocol(s) meet the specified criteria
Disease Site: Other
Protocol No.TitleStatus
1280-18An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive, HER2-, breast cancer, followed by expansion cohorts.Open
17-1493Expanded Access of Neratinib for Use with Capecitabine in Patients with Metastatic Breast Cancer and CNS MetastasisOpen (affiliates only)
17C0034A randomized, double blind phase II trial of Radiation Therapy plus Temozolomide and Pembrolizumab with and without HSPPC-96 in newly diagnosed Glioblastoma (GBM)Open
A011502-CIRB-REXRex_Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin As Adjuvant Therapy For Node Positive HER2 Negative Breast Cancer: The ABC TrialOpen (affiliates only)
A031102-CIRBA Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (Tip) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed By High-Dose Carboplatin And Etoposide (Ti-Ce) As First Salvage Treatment in Relapsed or Refractory Germ Cell TumorsOpen
AGCT1531A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell TumorsOpen
AMGEN359A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)Open (affiliates only)
AMGEN482A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Disease in Subjects With Newly Diagnosed Multiple MyelomaOpen (affiliates only)
ANBL1531A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)Open
ANHL1522A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP-specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)Open
APEC1621SCNCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)Open
ARO-021ARO-021- Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Inducation Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid LeukemiaOpen
ASG-22CE-13-2A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4Open
BMT-CTN-1506A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AMLOpen
DF-HCC17101-PACE DF-HCC 17-101: Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer (Protocol #: 17-101)Open
EAY131-AMATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard TreatmentOpen
ETCTN9767-CIRBAn Open Label, Multicenter, Single arm Phase II study to evaluate the Activity and Tolerability of the novel mTOR Inhibitor, MLN0128 (TAK-228), in patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the urothelial tract whose tumors harbor a TSC1 and/or a TSC2 mutation.Open
FADOI03-2016Apixaban for the Treatment of Venous Thromboembolism in Patients with Cancer: a Prospective Randomized Open Blinded End-Point (PROBE) Study - The Caravaggio StudyOpen
FEDR-MF-001FREEDOMA Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy and Safety Study of Fedratinib in Subjects with DIPSS-Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated with Ruxolitinib.Open
GU15-262Phase 2 Trial of Olaparib in Patients with Metastatic Urothelial Cancer Harboring DNA Damage Response Gene AlterationsOpen
INCB01158-206“A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma”Open
LCCC1725A Phase II Study of Durvalumab (MEDI 4736) with Radiotherapy for the adjuvant treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma Not Open
LCCC1907-ATL-COMCompassionate Use Re-Infusion of ATLCAR.CD30Open
LCCC1932-ATL-COMCompassionate Use Infusion of ATLCAR.CD30.CCR4Open
LOXO-BTK-18001A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin’s Lymphoma (NHL) Open
MIRATI-516-003A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial CarcinomaOpen
NCI-CT018-10129-CIRBA Phase 2 Study of PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid TumorsOpen
NRG-GU006A PHASE II, DOUBLE-BLINDED, PLACEBO-CONTROLLED RANDOMIZED TRIAL OF SALVAGE RADIOTHERAPY WITH OR WITHOUT ENHANCED ANTI-ANDROGEN THERAPY WITH APALUTAMIDE IN RECURRENT PROSTATE CANCEROpen
ODO-TE-B301A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a TaxaneOpen
ONC012A Phase II Study of ONC201 in Recurrent or Metastatic Type II Endometrial CancerOpen
PANTHERPANTHER: Prospective study of Apalutamide and Abiraterone Acetate iN ChemoTHerapy Naïve mEn with mCRPC Stratified by Race (PANTHER)Open
RTOG1008A Randomized Phase II/III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland TumorsClosed
S1702-CIRBS1702, CIRB " A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for patients with previously treated Al AmyloidosisOpen
SGN22E-002A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancerOpen
UAZ2016-08-02A Phase I safety and dose-finding trial of alternate-weekly, self-administered, intravaginal application of 5-fluorouracil and imiquimod for treatment of high-grade cervical intraepithelial lesionsOpen
UC13-0540Afatinib in advanced refractory urothelial cancerOpen